Northrop Grumman Lifts Outlook as Backlog Buildup Continues
By Dean Seal
Northrop Grumman raised its full-year guidance on the back of steady global demand.
The aerospace and defense company said it now expects $43.75 billion to $44.25 billion in sales in 2026, up from a previous target for $43.5 billion to $44 billion. Adjusted earnings should hit $28.60 to $29.10 a share instead of $27.40 to $27.90 a share as previously anticipated.
Chief Executive Kathy Warden said the company's backlog is surging to new records, thanks to robust global demand.
In the second quarter, the company posted a profit of $1.09 billion, or $7.68 a share, compared with $1.17 billion, or $8.15 a share, in the same quarter a year earlier. Analysts polled by FactSet had been expecting just $6.82 a share.
Total sales rose 5% to $10.88 billion, ahead of analyst targets for $10.8 billion. Northrop Grumman saw growth across its aeronautics, defense, mission and space segments.
Despite the top-line gains, operating income sank 38% in its defense systems segment and 16% in its space systems unit due to lower margins. Overall operating income was down 23%, primarily because of a $231 million gain from the year-earlier quarter due to a divestiture along with the margin compression in certain segments.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
July 21, 2026 07:46 ET (11:46 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
